Your browser doesn't support javascript.
loading
Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.
Aoki, Ami; Iwamura, Chiaki; Kiuchi, Masahiro; Tsuji, Kaori; Sasaki, Atsushi; Hishiya, Takahisa; Hirasawa, Rui; Kokubo, Kota; Kuriyama, Sachiko; Onodera, Atsushi; Shimada, Tadanaga; Nagaoka, Tetsutaro; Ishikawa, Satoru; Kojima, Akira; Mito, Haruki; Hase, Ryota; Kasahara, Yasunori; Kuriyama, Naohide; Nakamura, Sukeyuki; Urushibara, Takashi; Kaneda, Satoru; Sakao, Seiichiro; Nishida, Osamu; Takahashi, Kazuhisa; Kimura, Motoko Y; Motohashi, Shinichiro; Igari, Hidetoshi; Ikehara, Yuzuru; Nakajima, Hiroshi; Suzuki, Takuji; Hanaoka, Hideki; Nakada, Taka-Aki; Kikuchi, Toshiaki; Nakayama, Toshinori; Yokote, Koutaro; Hirahara, Kiyoshi.
Affiliation
  • Aoki A; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Iwamura C; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8510, Japan.
  • Kiuchi M; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Tsuji K; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
  • Sasaki A; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Hishiya T; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Hirasawa R; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Kokubo K; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Kuriyama S; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Onodera A; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Shimada T; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Nagaoka T; Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Ishikawa S; Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Kojima A; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, 113-8431, Japan.
  • Mito H; Funabashi Central Hospital, Chiba, 273-8556, Japan.
  • Hase R; Funabashi Central Hospital, Chiba, 273-8556, Japan.
  • Kasahara Y; Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, 286-0041, Japan.
  • Kuriyama N; Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, 286-0041, Japan.
  • Nakamura S; Department of Respiratory Medicine, Eastern Chiba Medical Center, Chiba, 283-8686, Japan.
  • Urushibara T; Department of Anesthesiology and Critical Care Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, 470-1192, Japan.
  • Kaneda S; Funabashi Municipal Medical Center, Chiba, 273-8588, Japan.
  • Sakao S; Kimitsu Chuo Hospital, Chiba, 292-0822, Japan.
  • Nishida O; Department of Gastroenterology, NHO Chiba Medical Center, Chiba, 260-8606, Japan.
  • Takahashi K; Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Chiba, 286-8520, Japan.
  • Kimura MY; Department of Anesthesiology and Critical Care Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, 470-1192, Japan.
  • Motohashi S; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, 113-8431, Japan.
  • Igari H; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
  • Ikehara Y; Department of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Nakajima H; Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Suzuki T; Department of Infectious Diseases, Chiba University Hospital, Chiba, 260-8677, Japan.
  • Hanaoka H; COVID-19 Vaccine Center, Chiba University Hospital, Chiba, 260-8677, Japan.
  • Nakada TA; Department of Pathology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Kikuchi T; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
  • Nakayama T; COVID-19 Vaccine Center, Chiba University Hospital, Chiba, 260-8677, Japan.
  • Yokote K; Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
  • Hirahara K; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
J Clin Immunol ; 44(4): 104, 2024 Apr 22.
Article in En | MEDLINE | ID: mdl-38647550
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Interferon Type I / Myeloid Cells / COVID-19 Limits: Female / Humans / Male Language: En Journal: J Clin Immunol Year: 2024 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Interferon Type I / Myeloid Cells / COVID-19 Limits: Female / Humans / Male Language: En Journal: J Clin Immunol Year: 2024 Type: Article Affiliation country: Japan